1. 76 Patients (PTS) with recurrent gynecologic cancer whose tumors have activating wnt pathway mutations respond better to DKN-01, a DICKKOPF-1 (DKK1) inhibitor. (18th September 2019) Authors: Arend, R; Castro, C; Matulonis, U; Hamilton, E; Gunderson, C; LyBarger, K; Goodman, H; Duska, L; Mahdi, H; ElNaggar, A; Kagey, M; Barroilhet, L; Bradley, W; Sachdev, J; O'Malley, D; Sirard, C; Birrer, M Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A40 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. (7th February 2019) Authors: Liu, J F; Barry, W T; Birrer, M; Lee, J -M; Buckanovich, R J; Fleming, G F; Rimel, B J; Buss, M K; Nattam, S R; Hurteau, J; Luo, W; Curtis, J; Whalen, C; Kohn, E C; Ivy, S P; Matulonis, U A Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗